AF Hezel, AC Kimmelman, BZ Stanger… - Genes & …, 2006 - genesdev.cshlp.org
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 …
Pancreatic ductal adenocarcinoma (PDAC) is driven by co-existing mutations in KRAS and TP53. However, how these mutations collaborate to promote this cancer is unknown. Here …
Pancreatic ductal adenocarcinoma (PDA), one of the deadliest human cancers, often involves somatic activation of K-Ras oncogenes. We report that selective expression of an …
The exocrine pancreas, consisting of ducts and acini, is the site of origin of pancreatitis and pancreatic ductal adenocarcinoma (PDAC). Our understanding of the genesis and …
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a high degree of inflammation and profound immune suppression. Here we identify Yes-associated protein …
N Habbe, G Shi, RA Meguid… - Proceedings of the …, 2008 - National Acad Sciences
Pancreatic ductal adenocarcinoma (PDAC) is believed to arise through a multistep model comprised of putative precursor lesions known as pancreatic intraepithelial neoplasia …
RH Hruban, K Brune, N Fukushima, A Maitra - Pancreatic Cancer, 2008 - Springer
Most pancreatic cancers are not diagnosed until after the cancer has spread to other organs and is no longer curable. As a result, the death rate for pancreatic cancer in this country …
JP De La O, LL Emerson… - Proceedings of the …, 2008 - National Acad Sciences
Efforts to model pancreatic cancer in mice have focused on mimicking genetic changes found in the human disease, particularly the activating KRAS mutations that occur in …